$CPRX News

HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals to Neutral, Lowers Price Target to $31.5

Catalyst Pharmaceuticals (NASDAQ:CPRX) Shows Strong Growth and a Bullish Technical Setup

Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story

UPDATE: Catalyst Pharmaceuticals Q1 Adj. EPS $0.79 Beats $0.46 Estimate, Sales $149.390M Beat $148.174M Estimate.

Catalyst Pharmaceuticals Q1 Sales $149.390M Beat $148.174M Estimate.

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen

Citigroup Downgrades Catalyst Pharmaceuticals to Neutral, Lowers Price Target to $31.5

Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion

Stephens & Co. Downgrades Catalyst Pharmaceuticals to Equal-Weight

Angelini Pharma To Acquire Catalyst Pharmaceuticals At $31.50 Per Share In Cash For $4.1B

Catalyst Pharmaceuticals shares are trading higher following a report suggesting that Italian drugmaker Angelini Pharma is exploring a potential acquisition of the company.

UPDATE: 'Italy's Angelini Said to Explore Acquisition of Catalyst Pharma' - Bloomberg News

Watching Catalyst Pharmaceuticals; Traders Circulate Unconfirmed Rumor The Company Is Seeing Takeover Interest

Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment

Catalyst Pharmaceuticals Says District Court Delays Bench Trial To May 18, 2026; Bench Trial Concerns Validity Of FIRDAPSE Patents Expiring In 2032, 2034, 2037

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case